•  
  •  
  •  
  •  

2025-10-07 22:56:39

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Revolt Motors fuels India's Racing Future with Sponsorship of Young Racer Ethan Joy at F4 India Championship
  • Simplex Realty Limited enters into supplemental agreement for redevelopment project
  • Ameenji Rubber Ltd. debuts on BSE SME Exchange
  • Mahanagar Gas Ltd signs MoU with Oil India Ltd to collaborate across the LNG value chain

Keywords Selected:  CadilaHealthcare

Research

  • Quant Pick - Cadila Healthcare - ICICI Direct

Stock Report

  • Zydus receives final approval from the USFDA for Empagliflozin and Metformin Hydrochloride Tablets
  • Zydus Lifesciences receives final approval from USFDA for Adapalene and Benzoyl Peroxide Topical Gel
  • Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets
  • Zydus announces publication of 'DREAM-ND' and 'DREAM-D' Phase 3 trials of Desidustat in 'American Journal of Nephrology'
  • Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection
  • Zydus to supply Sagent's Caffeine Citrate Oral Solution from Jarod, post USFDA's PAS Approval
  • The Lancet publishes Phase III data of ZyCoV-D
  • Zydus receives final approval from USFDA for Colestipol Hydrochloride Tablets
  • Zydus Lifesciences Ltd gets 3 observations from USFDA for Injectable Facility
  • Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets
  • Zydus to launch Oxemiaâ„¢ a breakthrough treatment for Anemia in patients suffering from CKD
  • Cadila Healthcare Limited is now Zydus Lifesciences Limited
  • Zydus receives final approval from USFDA for Dapagliflozin Tablets
  • Zydus gets 180 days shared exclusivity for Roflumilast Tablets
  • Cadila Healthcare consolidated Q3FY22 net profit slips to Rs. 500.4 crores
  • Zydus supplies the first consignment of its COVID-19 vaccine ZyCoV-D
  • Cadila Healthcare Ltd reappoints Dr. Sharvil P Patel as MD
  • Zydus receives final approval from USFDA for Vigabatrin Tablets
  • KPI Global Infrastructure signs new PPA for 3.10 MW solar power
  • Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules
  • Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets
  • Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria
  • Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor
  • Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules

Latest Post

  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Revolt Motors fuels India's Racing Future with Sponsorship of Young Racer Ethan Joy at F4 India Championship
  • Simplex Realty Limited enters into supplemental agreement for redevelopment project
  • Ameenji Rubber Ltd. debuts on BSE SME Exchange
  • Mahanagar Gas Ltd signs MoU with Oil India Ltd to collaborate across the LNG value chain


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024